Axsome Total Debt vs Current Liabilities Analysis
AXSM Stock | USD 69.71 0.90 1.31% |
Trend analysis of Axsome Therapeutics balance sheet accounts such as Short Long Term Debt Total of 195.7 M, Other Current Liabilities of 101.8 M or Total Current Liabilities of 145.8 M provides information on Axsome Therapeutics' total assets, liabilities, and equity, which is the actual value of Axsome Therapeutics to its prevalent stockholders. By breaking down trends over time using Axsome Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Axsome |
About Axsome Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Axsome Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Axsome Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Axsome Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Axsome currently owns. An asset can also be divided into two categories, current and non-current.
Axsome Therapeutics Balance Sheet Chart
Axsome Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Axsome Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Axsome Therapeutics' Cash is very stable compared to the past year. As of the 18th of April 2024, Cash And Short Term Investments is likely to grow to about 405.5 M, though Retained Earnings are likely to grow to (793.8 M). Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Axsome Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Axsome Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Axsome Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Axsome Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 18th of April 2024, Tax Provision is likely to grow to about 1 M, while Enterprise Value Over EBITDA is likely to drop (20.37).
Axsome Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Axsome Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Axsome Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.5M | 186.1M | (338.4M) | 331.5M | 588.2M | 617.6M | |
Short Long Term Debt Total | 19.9M | 50.1M | 49.7M | 94.7M | 186.4M | 195.7M | |
Other Current Liab | 683.2K | 8.7M | 9.3M | 57.5M | 96.9M | 101.8M | |
Total Current Liabilities | 24.5M | 23.4M | 23.1M | 96.6M | 138.9M | 145.8M | |
Total Stockholder Equity | (175.9M) | (278.8M) | (409.2M) | 109.6M | 191.0M | 200.5M | |
Net Debt | (200.0M) | (133.8M) | (36.8M) | (106.2M) | (199.8M) | (189.8M) | |
Retained Earnings | (175.9M) | (278.8M) | (409.2M) | (596.3M) | (835.6M) | (793.8M) | |
Accounts Payable | 10.9M | 13.5M | 13.1M | 38.6M | 40.7M | 42.7M | |
Cash | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Cash And Short Term Investments | 220.0M | 183.9M | 86.5M | 200.8M | 386.2M | 405.5M | |
Common Stock Total Equity | 3.0K | 3.7K | 3.7K | 3.8K | 4.3K | 2.7K | |
Common Stock Shares Outstanding | 34.0M | 37.2M | 37.6M | 40.7M | 45.4M | 30.1M | |
Liabilities And Stockholders Equity | (134.1M) | (206.5M) | (338.4M) | 331.5M | 588.2M | 617.6M | |
Other Current Assets | 413.1K | 148.4K | 45.3K | 2.8M | 8.1M | 8.5M | |
Other Stockholder Equity | (3.7K) | (3.7K) | (3.8K) | 705.9M | 1.0B | 1.1B | |
Total Liab | 41.8M | 72.3M | 70.8M | 221.9M | 397.3M | 417.1M | |
Total Current Assets | 220.4M | 184.0M | 86.5M | 245.6M | 504.3M | 529.5M | |
Short Term Debt | 2.6M | 1.2M | 620.7K | 424.7K | 1.3M | 1.3M | |
Common Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 3.2K | |
Net Tangible Assets | 178.7M | 113.8M | 15.6M | 39.6M | 45.5M | 52.6M | |
Non Current Assets Total | 170.5K | 2.1M | 1.3M | 85.8M | 84.0M | 88.2M | |
Non Currrent Assets Other | 139.9K | 317.4K | 322.9K | 14.7M | 11.0M | 11.6M | |
Other Assets | 139.9K | 2.1M | (426.1M) | 14.7M | 13.2M | 13.9M | |
Long Term Debt | 17.3M | 48.3M | 49.1M | 94.3M | 178.1M | 187.0M | |
Non Current Liabilities Total | 17.3M | 48.9M | 49.1M | 125.4M | 258.4M | 271.3M | |
Property Plant And Equipment Net | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant And Equipment Gross | 30.6K | 1.8M | 944.0K | 1.1M | 7.6M | 8.0M | |
Property Plant Equipment | 30.6K | 52.6K | 283.8K | 1.1M | 1.3M | 1.4M | |
Retained Earnings Total Equity | (107.6M) | (175.9M) | (278.8M) | (409.2M) | (368.3M) | (349.9M) | |
Long Term Debt Total | 3.6M | 17.3M | 48.3M | 49.1M | 56.5M | 59.3M | |
Capital Surpluse | 108.5M | 354.6M | 392.6M | 424.8M | 488.5M | 264.6M | |
Net Invested Capital | 198.7M | 162.1M | 64.7M | 203.8M | 369.0M | 387.5M | |
Net Working Capital | 195.9M | 160.6M | 63.5M | 149.1M | 365.4M | 383.7M | |
Capital Stock | 3.7K | 3.7K | 3.8K | 4.4K | 5K | 4.3K |
Axsome Therapeutics Investors Sentiment
The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.
Pair Trading with Axsome Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Axsome Stock
0.86 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.87 | ME | 23Andme Holding | PairCorr |
Moving against Axsome Stock
0.83 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
0.74 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.69 | DSGN | Design Therapeutics Upward Rally | PairCorr |
0.61 | VANI | Vivani Medical | PairCorr |
0.58 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Transaction History View history of all your transactions and understand their impact on performance |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.